BPI-452080 / Betta Pharma - LARVOL DELTA

Tianfeng Securities: Give Betta Pharmaceuticals an overweight rating [Google translation] (Securities Star) - "On August 26, Beida Pharmaceutical Company released its 2023 semi-annual report...Ensartinib has been included in the medical insurance catalog for both first- and second-line treatment indications, resulting in a significant increase in product sales. In the first half of 2023, sales increased by 12.02% year-on-year....The clinical trial applications for BPI-460372, BPI-452080, BPB-101, and BPI-472372 projects have been approved by the National Medical Products Administration (NMPA) and can begin. The clinical trial of the BPI-460372 project has been approved by the NMPA and the US Food and Drug Administration (FDA)."

IND • New trial • Sales • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Betta Pharmaceuticals' HIF-2α Inhibitor BPI-452080 Phase I Clinical Study First Subject Enrolled [Google translation] (Stockstar) - "According to the Securities Times, recently, the phase I clinical study of Betta Pharmaceuticals' BPI-452080 project completed the enrollment of the first subject. BPI-452080 is an inhibitor of hypoxia inducible factors 2α (HIF-2α). It is intended to be used in patients with locally advanced or advanced metastatic clear cell renal cell carcinoma, VHL disease-associated renal cell carcinoma, and other advanced solid tumors with genetic abnormalities in the HIF-2α signaling pathway."

Enrollment status • Genito-urinary Cancer • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Von Hippel-Lindau Syndrome

A Study of BPI-452080 in Subjects With Solid Tumors (clinicaltrials.gov) - P1 | N=87 | Not yet recruiting | Sponsor: Betta Pharmaceuticals Co., Ltd.

New P1 trial • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Von Hippel-Lindau Syndrome

BPI-452080: A potent and selective HIF-2α inhibitor for the treatment of clear cell renal cell carcinoma, von Hippel-Lindau disease, and other solid tumors (AACR 2023) - "In conclusion, BPI-452080 is a potent, selective, and orally bioavailable HIF-2α inhibitor which presents a novel therapeutic option for ccRCC, von Hippel-Lindau disease, and other solid tumors. BPI-452080 is planned to enter Phase I clinical trial in China in early 2023."

Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • CCND1 • CXCR4 • EPAS1 • HIF1A • SLC2A1